Recent evidence, however, suggests that DOACs might be considered for venous thromboembolic events in APS patients without the antiphospholipid “triple positivity” profile (i.e.,: LAC, anti-cardiolipin, and anti-beta-2-glycoprotein I positivity), which is associated with the highest risk of thrombotic events [28,119]. This evidence concerns the gene APOH and autoimmune polyendocrinopathy.